Category: Latest News

  • IDEAYA shares soar on positive late-stage melanoma trial data

    IDEAYA shares soar on positive late-stage melanoma trial data

    IDEAYA Biosciences (NASDAQ:IDYA) stock surged 27% on Monday after the company reported encouraging topline results from its Phase 2/3 registrational study evaluating darovasertib in combination with crizotinib for first-line treatment of metastatic uveal melanoma. The OptimUM-02 study achieved its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS). Patients receiving the combination…

  • Sandisk shares jump after Nasdaq-100 addition

    Sandisk shares jump after Nasdaq-100 addition

    Sandisk Corporation (NASDAQ:SNDK) shares climbed around 4% on Monday after the company was confirmed for inclusion in the Nasdaq-100 Index. Nasdaq said Sandisk will join the benchmark index ahead of the market open on April 20, 2026, replacing Atlassian Corporation (NASDAQ:TEAM). Being added to the Nasdaq-100 often boosts demand for a stock, as funds and…

  • Regeneron, Telix strike radiopharmaceutical cancer deal worth up to $2.1bn

    Regeneron, Telix strike radiopharmaceutical cancer deal worth up to $2.1bn

    Regeneron Pharmaceuticals (NASDAQ:REGN) has entered into a strategic collaboration with Telix Pharmaceuticals (NASDAQ:TLX) to develop and commercialize radiopharmaceutical therapies targeting cancer. As part of the agreement, Telix will receive an initial $40 million payment covering four early-stage therapeutic programs. Both companies will jointly fund development and split any resulting profits equally, while Telix will retain…

  • Wall Street set for lower open as renewed U.S.-Iran tensions unsettle markets: Dow Jones, S&P, Nasdaq, Futures

    Wall Street set for lower open as renewed U.S.-Iran tensions unsettle markets: Dow Jones, S&P, Nasdaq, Futures

    U.S. stock futures pointed to a weaker start on Monday, with equities likely to retreat after posting strong gains in the previous week. Investor sentiment has been dampened by rising fears of renewed escalation in the Middle East, following the collapse of weekend negotiations between Washington and Tehran. “They have chosen not to accept our…

  • Five key themes for markets in the week ahead

    Five key themes for markets in the week ahead

    Geopolitics is taking centre stage at the start of the trading week, with a planned U.S. blockade of the Strait of Hormuz driving fresh volatility across markets. The move has pushed oil prices higher again, while upcoming inflation data and a busy earnings calendar could provide further direction for investors. 1. U.S. moves ahead with…

  • McDonald’s plans energy drinks and new sodas for U.S. menu overhaul – WSJ

    McDonald’s plans energy drinks and new sodas for U.S. menu overhaul – WSJ

    McDonald’s (NYSE:MCD) is preparing to expand its beverage lineup in the U.S. with the launch of energy drinks and new flavoured sodas, as part of a broader effort to refresh its cold drink offering, according to a report by The Wall Street Journal. The company is expected to introduce several new drinks in the coming…

  • Meta develops AI version of Zuckerberg to engage with staff – FT

    Meta develops AI version of Zuckerberg to engage with staff – FT

    Meta Platforms (NASDAQ:META) is building an artificial intelligence-powered replica of its chief executive Mark Zuckerberg to interact with employees on his behalf, according to a report by the Financial Times citing sources familiar with the project. The company has been advancing photorealistic, AI-driven 3D avatars capable of real-time interaction, and has recently shifted focus toward…

  • Baker Hughes agrees $1.45bn sale of Waygate unit to Hexagon

    Baker Hughes agrees $1.45bn sale of Waygate unit to Hexagon

    Baker Hughes (NASDAQ:BKR) said Monday it has reached an agreement to divest its Waygate Technologies division to Swedish group Hexagon AB for $1.45 billion in cash. The disposal forms part of a wider strategic reshaping at Baker Hughes, as the company looks to streamline its portfolio and strengthen its balance sheet and liquidity position. Earlier…

  • Replimune plunges after second FDA setback for melanoma therapy; analysts turn bearish

    Replimune plunges after second FDA setback for melanoma therapy; analysts turn bearish

    Shares of Replimune Group (NASDAQ:REPL) tumbled sharply in premarket trading on Monday, falling close to 60% after the U.S. Food and Drug Administration issued a second complete response letter (CRL) for RP1, its oncolytic virus treatment being developed in combination with nivolumab for advanced melanoma. The stock was down more than 57% by 05:10 ET…

  • Oil jumps above $100, dollar strengthens and equities retreat as U.S. targets Iran shipping

    Oil jumps above $100, dollar strengthens and equities retreat as U.S. targets Iran shipping

    Oil prices surged on Monday after the United States moved to enforce a blockade on Iranian-linked shipping following the breakdown of weekend peace negotiations, while the dollar strengthened and both equities and bonds came under pressure. The U.S. action, intended to increase pressure on Tehran, has left a fragile ceasefire in jeopardy and prolonged uncertainty…